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| INTRODUC TI ON
Anti-Müllerian hormone (AMH) has become widely known as a marker of ovarian reserve in reproductive medicine, [1] [2] [3] 
and in
Japan, an increasing number of fertility centers are introducing the measurement of AMH. However, sometimes AMH analysis seems to be conducted without a thorough understanding of the significance of AMH measurement and ovarian reserve or adequate explanation to patients. The use of AMH measurement is expanding to a broad range of fields, for example, the assessment of ovarian reserve in women who will receive or have received cancer treatment. 
| MATERIAL S AND ME THODS
The correlation of AMH values measured by the Gen II pre-mix assay and the Access assay was assessed using 230 blood samples collected at our clinics before the introduction of the Access assay. In addition, data with an AMH value of <10 ng/mL (211 blood samples)
were evaluated excluding exceptionally high value of AMH. 
| RE SULTS
The AMH values measured by the Access assay were well correlated with those measured by the Gen II pre-mix assay. The AMH values measured just before oocyte retrieval by the Access assay and the number of oocytes retrieved after COS showed a good correlation with R = 0.655 ( Figure 2 ).
F I G U R E 1
Method comparison between the Access antiMüllerian hormone (AMH) assay and the Gen II pre-mix assay (230 blood samples)
The AMH, E2, and FSH levels in the poor, normal, and high response groups are presented in Figure 3 . The ROC analysis for differentiating the normal response group and the high response group revealed that the AUC for AMH was comparable with that for E2 and larger than that for FSH, indicating that AMH is a good marker of high response to ovary stimulation with sensitivity that was close to that of E2, a direct measure of follicular development, and higher than that of FSH ( Figure 4A ). The ROC analysis for differentiating the normal response group and the poor response group demonstrated that AMH was a useful marker of poor response to ovarian stimulation, with sensitivity that was lower than that of E2 but higher than that of FSH ( Figure 4B ).
Anti 
| D ISCUSS I ON
After many twists and turns, automated immunoassay systems are becoming mainstream as a method to measure AMH levels. 4 Instinctively, AMH measurement involves a high degree of variability and common measurement errors, as compared with the measurement of other hormones. Even so, AMH is thought to be an accurate predictor of ovarian reserve, because it is relatively stable with no major short-term changes throughout the menstrual cycle, unlike other hormonal markers that dramatically fluctuate within the menstrual cycle, such as FSH, LH, E2, and progesterone. The results of the study demonstrated the good correlation between AMH level and oocyte yield, suggesting that AMH may be very effective in predicting oocyte yield in IVF treatment. It is important to note, however, that AMH is not a good predictor of pregnancy or pregnancy potential as reported elsewhere. [6] [7] [8] AMH is an indicator reflecting the degree of primordial follicles remaining in the ovary, which is independent of whether fertilized oocytes can be developed in the uterus. Even so, it may be certain that high AMH levels suggestive of increased oocyte yields are somehow advantageous to the chance of pregnancy per oocyte retrieval; thus, the numerical superiority of oocyte yields may reflect pregnancy potential.
The degree of aging and damage of oocytes are biased, and if more oocytes are retrieved, there will be more opportunities to find less damaged oocytes. The impact of high AMH levels, however, may be smaller than that of the aging of oocytes, and accordingly, AMH
should not be used to predict pregnancy outcome or response to fertility treatment.
In this study, E2 level per oocyte retrieved was increased to ≈700 pg/mL around the age of 40, as compared with ≈650 pg/ mL below the age of 30. Similarly, E2 level per mature oocyte was increased to ≈1000 pg/mL around the age of 40 compared with ≈800 pg/mL below the age of 30. Although it has been stated that peak E2 level per mature oocyte is 200-400 pg/mL, 9 E2 levels per oocyte retrieved and per mature oocyte observed in clinical situations appear to increase with age. Also in this study, the E2 levels per oocyte were extremely higher. This may be partially explained by the process of dividing E2 levels by the number of oocytes actually retrieved, not oocytes detected, resulting in the higher mean E2 level per oocyte. In our clinical experience, even if 10 retrievable oocytes are found, the number of oocytes that can be actually retrieved is usually seven to nine and it is rare to be able to collect all the 10 oocytes. In any event, it is clear that a high E2 level is required to obtain a mature oocyte in patients of advanced age, especially in those with a low oocyte yield. The similar trend was noted for AMH that correlates well with oocyte yield; namely, a higher E2 level is required to obtain a mature oocyte in patients of advanced age, with a low AMH value.
These findings were similar to the results of a previously reported multicenter, observational study. 10 In this study, we measured AMH by the Access assays in more than 3000 Japanese women and the results indicated that AMH could be an accurate marker of ovarian response to stimulation as observed in the previous Gen II pre-mix
assay. This study also demonstrated that AMH levels are as sensitive as E2 levels measured just before oocyte retrieval, which are directly associated with oocyte yield, in predicting ovarian response. As a result, though FSH basal value used to be a good indicator of ovary 
